Hologic, Inc. (US), Becton, Dickinson and Company (US), and Leica Biosystems Nussloch GmbH (US) are the leading players in the breast lesion localization market. The Breast Lesion Localization Market is expected to reach USD 305 million by 2026 from USD 244 million in 2021, will grow at a CAGR of 4.6% during the forecast period. The growth of this market is mainly attributed to the growing incidence of breast cancer, the increasing rate of the geriatric population (as age contributes to the risk of breast cancer), the rising awareness on the early detection of breast cancer in the coming years and improved reimbursement scenario. However, several factors, such as errors in screening alongside misdiagnosis and uncertainty in regulatory approval procedures are expected to restrain the growth of the breast lesion localization market during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=35768623

Driver: Increasing incidence of breast cancer

Breast cancer is among the most common diseases affecting women in developed and developing countries. According to the American Cancer Society, breast cancer is the second-leading cause of cancer-related deaths in women across the globe. Globally, there has been significant growth in the number of breast cancer cases. This can majorly be attributed to changing lifestyles, the increasing use of oral contraceptives, and the growing number of women undergoing cosmetic surgeries, such as breast enhancement.

Growing rate of the aging population

With age, the risk of developing breast cancer increases. Aging increases multipotent progenitors (a type of adult stem cell at the root of many breast cancers) and decreases the number of myoepithelial cells, which line the breast’s milk-producing luminal cells and serve as tumor suppressors. According to the American Cancer Society, approximately 1 out of 8 invasive breast cancers develop in women less than 45 years. In contrast, approximately 2 out of 3 invasive breast cancers develop in women aged 55 and above.

The reasons such as growing incidence of breast cancer, growing ageing population and the rising awareness on the early detection of breast cancer contributes to the growth of breast lesion localization market. However, uncertainty in regulatory approval procedures can restrain the growth of the market during the forecast period.

Restraint: Uncertainty in regulatory approval procedures

Regulatory agencies such as the US FDA require comprehensive clinical data supporting the clinical safety and efficacy of a product under approval. With the presence of stringent regulatory requirements for product approval, players operating in the breast lesion localization methods (specially radioisotope localization) market need to obtain nuclear regulatory clearance from the Nuclear Regulatory Commission to ensure the safe use of radioactive seeds. This approval process is very lengthy and capital-intensive, which makes it difficult for small manufacturers and companies with limited budgets to sustain themselves in this market.

Opportunity: Emerging economies offer high growth potential

Developing economies, such as India, China, Brazil, South Korea, Turkey, Russia, and South Africa, offer high growth opportunities for the major players operating in the global market. A large population base—especially in India and China—offers a sustainable market for entire medical and surgical devices. As per GLOBOCAN 2020, the incidence of breast cancer in China is estimated to be 416,000 in 2020; this number is estimated to increase by 446,000 cases by 2025. Likewise, the number of women diagnosed with breast cancer is estimated to reach 272,000 in 2040 from 178,000 in 2020 in India. Breast cancer incidence among women aged more than 65 is expected to increase by ~61% and ~65% in India and China, respectively, by 2025.

View detailed Table of Content here@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=35768623

Breast Lesion Localization Market Dynamics

In terms of value, the wire localization segment accounted for the largest share of the breast lesion localization market in 2020.

Based on type, the breast lesion localization market is segmented into wire localization, radioisotope localization, magnetic localization, electromagnetic localization, and other localization methods. The wire localization segment accounted for the largest share of the breast lesion localization market in 2020. The appropriate localization of abnormal tissues, the minimum removal of normal tissues, minimum scarring, and the availability of reimbursement for breast lesion localization devices are the major factors driving the growth of the wire localization segment.

Radio-guided occult lesion localization (ROLL) segment accounted for alargest share of the radioisotope localization market in 2020

Radioisotope localization is used for preoperative nonpalpable lesion localization during breast cancer surgeries as well as for sentinel lymph node mapping in cancer staging. By type, the radioisotope localization methods market is segmented into radio-guided occult lesion localization (ROLL) and radioactive seed localization (RSL). Radio-guided occult lesion localization (ROLL)segment accounted for a largest share of the breast lesion localization market in 2020.

In 2020, the Breast Biopsy segment accounted for a largest share of the breast lesion localization market.

Based on usage, the breast lesion localization methods market is segmented into Breast Biopsy and Breast Conservation (Lumpectomy). In 2020, the Breast Biopsy segment accounted for a largest share of the breast lesion localization market. The factors driving the growth of the market are the growing incidence of breast cancer, the rising number of breast cancer screening programs, improved reimbursement scenarios, increased awareness of early detection of breast cancer, and greater demand for minimally invasive and non-invasive procedures.

Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=35768623

North America accounted for the largest share of the breast lesion localization market is 2020

The breast lesion localization market is segmented into four major regions, namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW).

North America accounted for the largest share of breast lesion localization market in terms of value during forecast period. APAC market is projected to grow at the highest CAGR due to the reasons such as increasing patient population, rising government spending on breast cancer research, increasing healthcare expenditure and increasing awareness about early detection of breast cancer.

Key players in the breast lesion localization market Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US), Laurane Medical LLC (France), Endomagnetics Ltd. (UK), Intramedical Imaging, LLC (US), Isoaid (US), Surgiceye GmbH (Germany), Ranfac Corp. (US), Mermaid Medical Group (Denmark), Izi Medical Products, LLC (US), MatekMedikal (Turkey), Tsunami Medical Srl (Italy), BPB Medica (Italy), Sirius Medical Systems B.V. (Netherlands), Molli Surgical Inc. (Canada). Other players in the breast lesion localization market are Sterylab S.R.L. (Italy), CP Medical (Georgia), MDL SRL (Italy), Biomedical Srl (Italy), Elucent Medical (US), Vigeosrl (Italy), and Medax Medical Devices (Italy).

View detailed Table of Content here @https://www.marketsandmarkets.com/Market-Reports/breast-lesion-localization-methods-market-35768623.html

Recent Developments:

• In January 2021, Hologic Inc. has completed the acquisition of Somatex Medical Technologies, which will enable Hologic Inc to strengthen their breast marker portfolio.

• In October 2020, Endomagnetics Ltd. launched a product named Magseed, which is implanted in the affected breast prior to the surgery, and through the use of a probe, can point out to the surgeon where exactly the cancerous tissue is located.

• In January 2019, IZI acquired Cook’s product portfolio of soft-tissue biopsy and breast localization needles. This will enable IZI to capture newer markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are moulded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit MarketsandMarkets™ or follow us on Twitter, LinkedIn and Facebook.